Jazz posts Phase 2 results for zanidatamab combo in GI cancers; JZP269 trial recruits

Jazz Pharmaceuticals had two trial updates posted on 2026-11-04.

• A Phase 2 study testing ZW25 (zanidatamab) plus standard first-line combination chemotherapy for safety, tolerability, and anti-tumor activity in selected gastrointestinal cancers¹ is listed as completed, with primary completion on 2025-08-30 and results first posted on 2026-11-04. The study enrolled 74 participants and covered patients with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma, biliary tract cancer, or colorectal cancer¹. The primary outcomes included confirmed objective response rate, defined as the number of participants achieving a complete or partial response per RECIST version 1.1¹.
• A Phase 1 study of JZP269, sponsored by Jazz Pharmaceuticals with Jazz Pharmaceuticals Ireland Limited as collaborator, is recruiting. The trial is designed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of JZP269, an orexin-2 receptor agonist, in healthy participants², with an estimated enrollment of 212 participants and primary completion estimated for 2027-02-27.